about
Paediatric acute myeloid leukaemia with the t(7;12)(q36;p13) rearrangement: a review of the biological and clinical management aspectsmiR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.Application of International Caries Detection and Assessment System (ICDAS) and Caries Management by Risk Assessment (CAMBRA) systems in child cancer patients: a clinical case report.Recurrent translocation t(10;17)(p15;q21) in minimally differentiated acute myeloid leukemia results in ZMYND11/MBTD1 fusion.Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing.Peptidomimetic blockade of MYB in acute myeloid leukemia.MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia.Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic TransformationLow-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
P2860
Q26775693-84F9A529-BA41-4A3D-8196-7901BC33D291Q33872395-2E067AD2-8C28-4F50-A59C-4A3D026BFDB0Q34548815-1F6EEEF8-326A-4797-9381-31F53F283A92Q39170500-25E4AB35-AA71-4ECF-B380-CCF5A3804D12Q40213974-A7D6A154-48DE-4DBD-8632-6D1B6528DF13Q40273592-D4CF3212-9006-4BF2-9972-1541A824E757Q40526958-646E54BC-6749-4415-B627-EF726B303E59Q42176458-2D83C848-C925-4884-96A2-BE7ED71B79A5Q42322251-24C98EB2-5171-40B2-B6DA-8FCA4FE4CDB3Q47215625-7305DD56-D353-4D28-BA4D-2F4E2D02D593Q50066248-1CAACC43-750D-4AA0-BD11-B6126166A426Q51000809-D25A1976-E8D6-43BA-B23C-3BA048F395F4Q57293716-7CD15446-1F53-41F0-9DE4-93BB303B5DA7Q57809333-F6EE3205-F44D-4947-9B09-CA8A3FFEDECD
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pediatric AML: From Biology to Clinical Management
@ast
Pediatric AML: From Biology to Clinical Management
@en
Pediatric AML: From Biology to Clinical Management
@nl
type
label
Pediatric AML: From Biology to Clinical Management
@ast
Pediatric AML: From Biology to Clinical Management
@en
Pediatric AML: From Biology to Clinical Management
@nl
prefLabel
Pediatric AML: From Biology to Clinical Management
@ast
Pediatric AML: From Biology to Clinical Management
@en
Pediatric AML: From Biology to Clinical Management
@nl
P2860
P3181
P356
P1476
Pediatric AML: From Biology to Clinical Management
@en
P2093
C Michel Zwaan
Jasmijn D E de Rooij
P2860
P304
P3181
P356
10.3390/JCM4010127
P407
P577
2015-01-01T00:00:00Z